Foundation review: Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies

被引：23

作者：

Broussalis, Erasmia ^{[1
,2
]}

Trinka, Eugen ^{[1
]}

Killer, Monika ^{[1
,2
]}

Harrer, Andrea ^{[1
]}

McCoy, Mark ^{[3
]}

Kraus, Joerg ^{[1
]}

机构：

[1] Paracelus Med Univ Salzburg, Christian Doppler Klin, Dept Neurol, A-5020 Salzburg, Austria

[2] Paracelus Med Univ Salzburg, Christian Doppler Klin, Res Inst Neurointervent, A-5020 Salzburg, Austria

[3] Paracelus Med Univ Salzburg, Christian Doppler Klin, Dept Radiol & MRT, A-5020 Salzburg, Austria

来源：

DRUG DISCOVERY TODAY | 2012年 / 17卷 / 13-14期

关键词：

FOCAL CEREBRAL-ISCHEMIA; TISSUE-PLASMINOGEN ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; RAT MODEL; RT-PA; ISCHEMIA/REPERFUSION INJURY; HEMORRHAGIC TRANSFORMATION; POTENT NEUROPROTECTION; CILOSTAZOL PROTECTS;

D O I：

10.1016/j.drudis.2012.02.011

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Stroke still remains a major healthcare problem. The growing understanding of the mechanism of cell death in ischemia leads to new approaches in stroke treatment. The aim of neuroprotection is to reduce the post-stroke impairment and the overall costs that are accompanied in patients with severe disability. Despite encouraging data from experimental animal models, almost all neuroprotective therapies have, to date, not been established in clinical routine. In this part B of our review on stroke therapies we provide an overview on future candidates in stroke therapy and neuroprotective agents that are under investigation.

引用

页码：671 / 684

页数：14

共 103 条

[1]

Baseline NIH Stroke Scale score strongly predicts outcome after stroke - A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) [J].